Exclusive Summary

• - Multi-pharmacopoeia API (JP/BP/EP/KP) plus 0.3% strength in 0.4 mL unit-dose enables fast multi-country registrations and meets preservative-free preferences.
• - Large and sticky demand: 300–500M people with dry-eye symptoms globally, 28–30M cataract surgeries/year, and ~140M contact-lens wearers.
• - Recognized first-line by AAO and TFOS DEWS II; 0.3% hyaluronate shows stronger and longer symptom/staining improvement in moderate-to-severe DED.
• - Highly genericized yet fragmented market; high-strength, preservative-free unit-dose plus value pricing can win in both premium self-pay and institutional channels.
• - Distribution-ready asset with 30–60% price advantage vs brands and dual registration routes (device/drug); Vietnam requires direct local partner (no China agency).